RT期刊文章SR电子T1恶化的影响历史的结果影响审判摩根富林明欧洲呼吸杂志乔和J FD欧元欧洲呼吸学会SP 1901921 10.1183/13993003.01921 -2019签证官55 5 A1大卫M.G.哈尔平A1马克t Dransfield A1美兰k .汉A1 c·伊莱恩·琼斯A1莎莉基尔布赖德188bet官网地址A1彼得·兰格A1 David a .利普森A1 David a . Lomas A1费尔南多·J·马丁内斯A1史蒂夫•帕斯科A1戴夫·辛格A1罗伯特智慧A1杰拉德J。克里内年2020 UL //www.qdcxjkg.com/content/55/5/1901921.abstract AB影响,52周,随机,双盲试验,评估的有效性和安全性fluticasone糠酸盐/ umeclidinium vilanterol (FF / UMEC / VI)三联疗法和FF / VI或UMEC / VI在慢性阻塞性肺病患者症状和发作的历史。子群分析评估的有效性是否FF / UMEC / VI和FF / VI或UMEC / VI和UMEC / VI和FF / VI变化根据之前恶化的历史,和恶化的历史和血液嗜酸性粒细胞计数。三个子组被定义:单温和(1中度/不严重;n = 3056(30%)),频繁温和(≥2中度/不严重;n = 4628(45%))和严重(≥1严重/任何温和;n = 2671 (26%))。终端包括年度治疗中度/重度恶化率(预先确定),肺功能和健康状况(因果)。中度/重度恶化率(降低% (95% CI))减少FF / UMEC /第六组和FF / VI(单身温和的20%(10-29),频繁的温和的11%(三分之一),严重的17%(7-26))和与UMEC / VI(单身温和的18%(5-29),温和的29%(21-37)频繁,严重的26% (14-35))。中度/重度恶化率减少了FF /第六组与UMEC / VI频繁的温和的子群;观察一个数值减少严重的子群(单身温和的2%(−12 - 18),频繁的温和的21%(11-29),严重的11% (−3-22))。中度/重度恶化率低的FF /第六组相比UMEC / VI患者高嗜酸性粒细胞计数。 FF/UMEC/VI improved lung function and health status versus both dual therapies irrespective of exacerbation subgroup. UMEC/VI improved lung function versus FF/VI in all subgroups.Triple therapy was more effective than dual regardless of exacerbation history, consistent with results in the intent-to-treat population. Comparisons between dual therapies were influenced by prior exacerbation history and eosinophil counts.FF/UMEC/VI shows benefits vs FF/VI and UMEC/VI across multiple endpoints irrespective of exacerbation history. Exacerbation history and eosinophils influenced the comparison between UMEC/VI and FF/VI, and eosinophils that between FF/UMEC/VI and UMEC/VI. http://bit.ly/2SHu2ey